Enliven Therapeutics's total assets for Q1 2024 were $342.78M, an increase of 25.08% from the previous quarter. ELVN total liabilities were $25.07M for the fiscal quarter, a 103.90% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.